clinical trial · NCT04950075
Study of INBRX-109 in Conventional Chondrosarcoma
Conventional ChondrosarcomaINBRX-109Placebo
brief summary
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
started
Sep 23, 2021
primary completion
Sep 30, 2025
completion
Dec 1, 2026
last updated
Jan 9, 2026
detailed description
This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
official title
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol